Cleveland Clinic, Muscle Atrophy. Accessed April 6, 2025
A small percentage of patients (10-15%) report mild, intermittent nausea even at therapeutic doses after months of treatment
2 Currently, the only GLP-1 receptor agonists licensed for weight management are Saxenda, Wegovy and Mounjaro
The lawsuits claim Novo Nordisk failed to adequately warn of NAION risks, despite emerging data from multiple studies
GLP-1 & GIP therapy targets GLP-1 and glucagon receptors on pancreatic beta cells, boosting insulin release
By offering judgment-free support, grounded information, and tools for behavior change, you help ensure that any decisionwhether to pursue medication or notis rooted in long-term well-being, not quick fixes